ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Another Epigenetics Agreement Signed

by Patricia L. Short
April 27, 2009 | APPEARED IN VOLUME 87, ISSUE 17

U .K.-based biotech company CellCentric has added two university professors—Ramin Shiekhattar and Luciano Di Croce, both of Barcelona's Center for Genomic Regulation—to its research network. The deal gives CellCentric 25 such agreements with labs around the world. CellCentric says it is building a portfolio of epigenetic-related technologies, including screens and markers. It also has six small-molecule discovery programs under way. Epigenetics is an emerging field investigating the processes that help govern chromatin structure and function, by which cell fate is controlled (C&EN, April 6, page 28).

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment